Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Pacific Biosciences Of California Inc's Business Segments
Pacific Biosciences Of California Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 37
Regions Reported
3
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable0%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 37 | - |
Revenue Share by Region - Q1 FY2026
- Americas45.3%
- EMEA29.2%
- Asia Pacific26.4%
Revenue by Geographic Region - Q1 FY2026
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Americas | $ 17 | 45.3% |
| EMEA | $ 11 | 29.2% |
| Asia Pacific | $ 10 | 26.4% |
Revenue by Product & Service Category - Q1 FY2026
- Product85.6%
- Consumable59.2%
- Instrument26.4%
- Service and Other15.3%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 32 | 85.6% |
| Consumable | $ 22 | 59.2% |
| Instrument | $ 10 | 26.4% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Pacific Biosciences Of California Inc dataset.
Description of Pacific Biosciences Of California Inc
Pacific Biosciences of California Inc.
(also known as PacBio) is an American biotechnology company founded in 2004 by Stephen Turner and Jonas Korlach.
The company is headquartered in Menlo Park, California, and specializes in advanced DNA sequencing technology.
PacBio aims to revolutionize the field of genomics and personalize medicine through its innovative sequencing technology.
The company's flagship product is the PacBio Sequel System, which is a high-throughput DNA sequencing instrument that uses Single Molecule, Real-Time (SMRT) technology.
This technology allows for the real-time observation of DNA replication, leading to highly accurate and long-read sequencing results.
The system can detect various types of genomic variations, including non-coding DNA, structural variations, and epigenetic modifications.
PacBio's sequencing technology has numerous applications, including studies of genetic diseases, cancer research, microbiome analysis, and forensic analysis.
The company has collaborations with major academic institutions and research centers worldwide, such as the Wellcome Trust Sanger Institute, the Broad Institute, and the Max Planck Institute.
In 2020, PacBio merged with a special purpose acquisition company (SPAC) called Schrödinger to go public.
The combined company trades on the Nasdaq under a new ticker symbol, "PACB.
" In summary, Pacific Biosciences Of California Inc is a biotech firm known for inventing and producing advanced DNA sequencing technology that allows for highly accurate and long-read sequencing results used for study of genetic diseases, cancer research, microbiome analysis and forensic analysis.
The company has collaborations with major academic institutions worldwide and went public in 2020 in collaboration with Schrödinger through SPAC.
(also known as PacBio) is an American biotechnology company founded in 2004 by Stephen Turner and Jonas Korlach.
The company is headquartered in Menlo Park, California, and specializes in advanced DNA sequencing technology.
PacBio aims to revolutionize the field of genomics and personalize medicine through its innovative sequencing technology.
The company's flagship product is the PacBio Sequel System, which is a high-throughput DNA sequencing instrument that uses Single Molecule, Real-Time (SMRT) technology.
This technology allows for the real-time observation of DNA replication, leading to highly accurate and long-read sequencing results.
The system can detect various types of genomic variations, including non-coding DNA, structural variations, and epigenetic modifications.
PacBio's sequencing technology has numerous applications, including studies of genetic diseases, cancer research, microbiome analysis, and forensic analysis.
The company has collaborations with major academic institutions and research centers worldwide, such as the Wellcome Trust Sanger Institute, the Broad Institute, and the Max Planck Institute.
In 2020, PacBio merged with a special purpose acquisition company (SPAC) called Schrödinger to go public.
The combined company trades on the Nasdaq under a new ticker symbol, "PACB.
" In summary, Pacific Biosciences Of California Inc is a biotech firm known for inventing and producing advanced DNA sequencing technology that allows for highly accurate and long-read sequencing results used for study of genetic diseases, cancer research, microbiome analysis and forensic analysis.
The company has collaborations with major academic institutions worldwide and went public in 2020 in collaboration with Schrödinger through SPAC.
Pacific Biosciences of California Inc (PacBio) is a leading biotechnology company at the forefront of genomic sequencing technology. With its headquarters in Menlo Park, California, PacBio operates on a global scale, catering to the needs of researchers and clinicians across North America, Europe, and the Asia Pacific. As a pioneer in advanced sequencing systems, PacBio provides a range of products and services that empower scientists and healthcare professionals to delve deeper into genetic analysis.
Segments
1. Genomic Sequencing:
The primary segment of PacBio is Genomic Sequencing, characterized by the design, development, and marketing of sequencing systems, consumables, and software. The core offering includes their innovative Sequel and Sequel II systems, which utilize Single Molecule, Real-Time (SMRT) sequencing technology. This long-read sequencing capability differentiates PacBios products, allowing researchers to achieve remarkable accuracy and resolution when analyzing genes, mutations, and genomic variations. This segment is a cornerstone for applications in academic research, agriculture, and pharmaceutical development, enabling comprehensive genome mapping and structural variant detection.
2. Clinical Diagnostics:
The Clinical Diagnostics segment focuses on the development of genomic assays and diagnostic tests aimed at identifying genetic diseases and disorders. PacBio’s clinical products strive to deliver accurate and holistic diagnostic information to clinicians, empowering them to make informed medical decisions. By creating assays that utilize long-read sequencing technology, PacBios clinical offerings can uncover complex genetic insights that traditional methods may miss, thus improving patient outcomes.
Products and Services
1. Sequencing Systems:
PacBio’s flagship products are their Sequel and Sequel II systems, which employ cutting-edge SMRT sequencing technology. These high-performance instruments are designed for diverse applications, including genome assembly, structural variant detection, and the mapping of complex genomic regions. The long-read capabilities of these systems make them especially useful in areas such as de novo sequencing and examining difficult-to-map regions of the genome.
2. Consumables:
PacBio supplies a comprehensive array of consumables essential for optimizing sequencing workflows. Key consumables include SMRT cells and SMRT reagents, which are integral to the sequencing process. Additionally, sample preparation kits and library preparation kits are provided to facilitate user-friendly workflows that maximize yield and performance while maintaining high-quality sequencing results. These consumables are designed to support high sample throughput and ensure consistency across experiments.
3. Software:
To complement its hardware offerings, PacBio provides a suite of advanced software tools tailored for data analysis and interpretation. The SMRT Link software platform serves as the primary data management and analysis interface, offering various workflows for different types of genomic data. It includes tools for alignment, variant calling, and visualization, helping researchers efficiently interpret vast datasets generated by sequencing experiments.
4. Clinical Diagnostics:
In the realm of clinical diagnostics, PacBio offers CLIA-certified SMRT Sequencing services that enable clinical laboratories to generate accurate and comprehensive diagnostic data. These services are pivotal for clinical applications, ranging from hereditary disease testing to oncology, allowing healthcare providers to better understand complex genetic conditions and tailor treatments accordingly.
5. Genomic Services:
Apart from products, PacBio also runs a genomic services division that provides whole genome sequencing, transcriptome sequencing, epigenome sequencing, and microbial sequencing. These services cater to academic, commercial, and governmental research entities requiring high-quality and personalized sequencing. PacBio’s dedicated support helps customers across industries realize their research goals, whether they are investigating genetic diseases, biodiversity, or agricultural traits.
Conclusion
Overall, Pacific Biosciences of California Inc stands out for its commitment to advancing genomic technologies. Its extensive range of products and services facilitates groundbreaking research and clinical applications, unlocking the potential of genomics across multiple fields. By leveraging long-read sequencing technology, PacBio enables greater precision in identifying genetic variations and mutations, leading to transformative insights in both basic research and clinical practice.
Segments
1. Genomic Sequencing:
The primary segment of PacBio is Genomic Sequencing, characterized by the design, development, and marketing of sequencing systems, consumables, and software. The core offering includes their innovative Sequel and Sequel II systems, which utilize Single Molecule, Real-Time (SMRT) sequencing technology. This long-read sequencing capability differentiates PacBios products, allowing researchers to achieve remarkable accuracy and resolution when analyzing genes, mutations, and genomic variations. This segment is a cornerstone for applications in academic research, agriculture, and pharmaceutical development, enabling comprehensive genome mapping and structural variant detection.
2. Clinical Diagnostics:
The Clinical Diagnostics segment focuses on the development of genomic assays and diagnostic tests aimed at identifying genetic diseases and disorders. PacBio’s clinical products strive to deliver accurate and holistic diagnostic information to clinicians, empowering them to make informed medical decisions. By creating assays that utilize long-read sequencing technology, PacBios clinical offerings can uncover complex genetic insights that traditional methods may miss, thus improving patient outcomes.
Products and Services
1. Sequencing Systems:
PacBio’s flagship products are their Sequel and Sequel II systems, which employ cutting-edge SMRT sequencing technology. These high-performance instruments are designed for diverse applications, including genome assembly, structural variant detection, and the mapping of complex genomic regions. The long-read capabilities of these systems make them especially useful in areas such as de novo sequencing and examining difficult-to-map regions of the genome.
2. Consumables:
PacBio supplies a comprehensive array of consumables essential for optimizing sequencing workflows. Key consumables include SMRT cells and SMRT reagents, which are integral to the sequencing process. Additionally, sample preparation kits and library preparation kits are provided to facilitate user-friendly workflows that maximize yield and performance while maintaining high-quality sequencing results. These consumables are designed to support high sample throughput and ensure consistency across experiments.
3. Software:
To complement its hardware offerings, PacBio provides a suite of advanced software tools tailored for data analysis and interpretation. The SMRT Link software platform serves as the primary data management and analysis interface, offering various workflows for different types of genomic data. It includes tools for alignment, variant calling, and visualization, helping researchers efficiently interpret vast datasets generated by sequencing experiments.
4. Clinical Diagnostics:
In the realm of clinical diagnostics, PacBio offers CLIA-certified SMRT Sequencing services that enable clinical laboratories to generate accurate and comprehensive diagnostic data. These services are pivotal for clinical applications, ranging from hereditary disease testing to oncology, allowing healthcare providers to better understand complex genetic conditions and tailor treatments accordingly.
5. Genomic Services:
Apart from products, PacBio also runs a genomic services division that provides whole genome sequencing, transcriptome sequencing, epigenome sequencing, and microbial sequencing. These services cater to academic, commercial, and governmental research entities requiring high-quality and personalized sequencing. PacBio’s dedicated support helps customers across industries realize their research goals, whether they are investigating genetic diseases, biodiversity, or agricultural traits.
Conclusion
Overall, Pacific Biosciences of California Inc stands out for its commitment to advancing genomic technologies. Its extensive range of products and services facilitates groundbreaking research and clinical applications, unlocking the potential of genomics across multiple fields. By leveraging long-read sequencing technology, PacBio enables greater precision in identifying genetic variations and mutations, leading to transformative insights in both basic research and clinical practice.